Cargando…

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms. The available pharmacological treatment is of a symptomatic nature and, as such, it does not modify the cause of AD. The currently used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miziak, Barbara, Błaszczyk, Barbara, Czuczwar, Stanisław J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152728/ https://www.ncbi.nlm.nih.gov/pubmed/34068096 http://dx.doi.org/10.3390/ph14050458

Ejemplares similares

Epilepsy in Pregnancy—Management Principles and Focus on Valproate
por: Błaszczyk, Barbara, et al.
Publicado: (2022)

Apitherapy in Post-Ischemic Brain Neurodegeneration of Alzheimer’s Disease Proteinopathy: Focus on Honey and Its Flavonoids and Phenolic Acids
por: Pluta, Ryszard, et al.
Publicado: (2023)

Post-Ischemic Permeability of the Blood–Brain Barrier to Amyloid and Platelets as a Factor in the Maturation of Alzheimer’s Disease-Type Brain Neurodegeneration
por: Pluta, Ryszard, et al.
Publicado: (2023)

Second Generation of Antiepileptic Drugs and Oxidative Stress
por: Kośmider, Kamil, et al.
Publicado: (2023)

Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
por: Miziak, Barbara, et al.
Publicado: (2022)

Editorial: Epilepsy and endocrine function
por: Miziak, Barbara, et al.
Publicado: (2023)

Anti-Epileptogenic Effects of Antiepileptic Drugs
por: Miziak, Barbara, et al.
Publicado: (2020)

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
por: Błaszczyk, Barbara, et al.
Publicado: (2010)

Neurosteroids and Seizure Activity
por: Miziak, Barbara, et al.
Publicado: (2020)

Selected Molecular Targets for Antiepileptogenesis
por: Pawlik, Marek J., et al.
Publicado: (2021)

Clinical utility of adjunctive retigabine in partial onset seizures in adults
por: Rejdak, Konrad, et al.
Publicado: (2012)

Ketogenic Diet in Alzheimer’s Disease
por: Rusek, Marta, et al.
Publicado: (2019)

Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer’s Disease Proteinopathy
por: Pluta, Ryszard, et al.
Publicado: (2021)

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
por: Prikhodko, Veronika A., et al.
Publicado: (2022)

The Dual Role of Glutamatergic Neurotransmission in Alzheimer’s Disease: From Pathophysiology to Pharmacotherapy
por: Bukke, Vidyasagar Naik, et al.
Publicado: (2020)

Gut microbiota and pro/prebiotics in Alzheimer’s disease
por: Pluta, Ryszard, et al.
Publicado: (2020)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

The Many Faces of Post-Ischemic Tau Protein in Brain Neurodegeneration of the Alzheimer’s Disease Type
por: Pluta, Ryszard, et al.
Publicado: (2021)

Neuroprotective and Neurological/Cognitive Enhancement Effects of Curcumin after Brain Ischemia Injury with Alzheimer’s Disease Phenotype
por: Pluta, Ryszard, et al.
Publicado: (2018)

Molecular Hydrogen Neuroprotection in Post-Ischemic Neurodegeneration in the Form of Alzheimer’s Disease Proteinopathy: Underlying Mechanisms and Potential for Clinical Implementation—Fantasy or Reality?
por: Pluta, Ryszard, et al.
Publicado: (2022)

Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer’s Disease
por: Roland, Joshua P., et al.
Publicado: (2021)

Brain Ischemia as a Prelude to Alzheimer's Disease
por: Pluta, Ryszard, et al.
Publicado: (2021)

Combination pharmacotherapy in Alzheimer's disease
por: Mintzer, Jacobo, et al.
Publicado: (2003)

Shared Genomic and Proteomic Contribution of Amyloid and Tau Protein Characteristic of Alzheimer’s Disease to Brain Ischemia
por: Pluta, Ryszard, et al.
Publicado: (2020)

Post-Ischemic Brain Neurodegeneration in the Form of Alzheimer’s Disease Proteinopathy: Possible Therapeutic Role of Curcumin
por: Pluta, Ryszard, et al.
Publicado: (2022)

Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2019)

Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
por: Cheong, Siew Lee, et al.
Publicado: (2022)

Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer’s Disease
por: Pluta, Ryszard, et al.
Publicado: (2021)

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
por: Cummings, Jeffrey L., et al.
Publicado: (2019)

Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
por: Miculas, Denisa Claudia, et al.
Publicado: (2022)

Proteomic and Genomic Changes in Tau Protein, Which Are Associated with Alzheimer’s Disease after Ischemia-Reperfusion Brain Injury
por: Ułamek-Kozioł, Marzena, et al.
Publicado: (2020)

Drug candidates in clinical trials for Alzheimer’s disease
por: Hung, Shih-Ya, et al.
Publicado: (2017)

Cross-Talk between Amyloid, Tau Protein and Free Radicals in Post-Ischemic Brain Neurodegeneration in the Form of Alzheimer’s Disease Proteinopathy
por: Pluta, Ryszard, et al.
Publicado: (2022)

The Role of the JAK/STAT Signaling Pathway in the Pathogenesis of Alzheimer’s Disease: New Potential Treatment Target
por: Rusek, Marta, et al.
Publicado: (2023)

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease
por: Lawn, Timothy, et al.
Publicado: (2021)

Kidney Drug Transporters in Pharmacotherapy
por: Łapczuk-Romańska, Joanna, et al.
Publicado: (2023)

Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease
por: Guzior, Natalia, et al.
Publicado: (2015)

Drug Interactions in Parkinson’s Disease: Safety of Pharmacotherapy for Arterial Hypertension
por: Bitner, Anna, et al.
Publicado: (2015)

Efficacy of pharmacotherapy and non-pharmacotherapy of Alzheimer dementia: A protocol for systematic review and meta-analysis
por: Boongird, Chitima, et al.
Publicado: (2022)

Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
por: Husna Ibrahim, Nurul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1uo9ij94kn8p3oriaoteg30n7u